MAPT and Alzheimer disease: In 2018, the National Institute on Aging–Alzheimer’s Association (NIA-AA) responded to this need, proposing a set of research criteria for the biological diagnosis of AD that, regardless of clinical symptoms, requires evidence of abnormalities in both beta amyloid (Aβ) biomarkers (“A”: CSF Aβ, amyloid-PET) and phosphorylated tau (pTau) biomarkers (“T”: CSF pTau, tau-PET) [14].